SG11202107774QA - N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof - Google Patents
N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereofInfo
- Publication number
- SG11202107774QA SG11202107774QA SG11202107774QA SG11202107774QA SG11202107774QA SG 11202107774Q A SG11202107774Q A SG 11202107774QA SG 11202107774Q A SG11202107774Q A SG 11202107774QA SG 11202107774Q A SG11202107774Q A SG 11202107774QA SG 11202107774Q A SG11202107774Q A SG 11202107774QA
- Authority
- SG
- Singapore
- Prior art keywords
- heterocyclic
- pharmaceutical composition
- membered ring
- capsid protein
- protein assembly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910073465 | 2019-01-25 | ||
PCT/CN2019/108483 WO2020151252A1 (en) | 2019-01-25 | 2019-09-27 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202107774QA true SG11202107774QA (en) | 2021-08-30 |
Family
ID=71735881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202107774QA SG11202107774QA (en) | 2019-01-25 | 2019-09-27 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220185774A1 (en) |
EP (1) | EP3915972A4 (en) |
JP (1) | JP7479384B2 (en) |
KR (1) | KR20210119452A (en) |
CN (1) | CN113365979B (en) |
AU (1) | AU2019424375B2 (en) |
CA (1) | CA3127393A1 (en) |
EA (1) | EA202092159A1 (en) |
SG (1) | SG11202107774QA (en) |
WO (1) | WO2020151252A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115974753A (en) | 2018-03-30 | 2023-04-18 | 正大天晴药业集团股份有限公司 | N-containing heterocyclic five-membered ring compound and application |
CN113549079A (en) | 2018-05-25 | 2021-10-26 | 正大天晴药业集团股份有限公司 | 2, 3-dihydro-1H-pyrrolizine-7-formamide derivatives and application thereof |
AU2020355384A1 (en) * | 2019-09-29 | 2022-05-05 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystalline form of capsid protein assembly inhibitor containing N hetero five-membered ring, and application thereof |
WO2021058001A1 (en) * | 2019-09-29 | 2021-04-01 | 正大天晴药业集团股份有限公司 | Crystal form of five-membered n heterocyclic compound, and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3603B1 (en) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
LT3024819T (en) | 2013-07-25 | 2018-06-11 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JP6452119B2 (en) * | 2013-10-23 | 2019-01-16 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Carboxamide derivatives and their use as pharmaceuticals for the treatment of hepatitis B |
EA201892034A1 (en) | 2016-03-09 | 2019-04-30 | Эмори Юниверсити | ELIMINATION OF HEPATITIS B VIRUS WITH THE HELP OF ANTI-VIRUS AGENTS |
JOP20190024A1 (en) * | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | Substituted pyrrolizine compounds and uses thereof |
CN113429341A (en) * | 2016-09-18 | 2021-09-24 | 正大天晴药业集团股份有限公司 | Novel capsid protein assembly inhibitors |
CN111788204B (en) * | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | Substituted pyrrolizine compounds as inhibitors of HBV replication |
CN115974753A (en) * | 2018-03-30 | 2023-04-18 | 正大天晴药业集团股份有限公司 | N-containing heterocyclic five-membered ring compound and application |
-
2019
- 2019-03-29 EA EA202092159A patent/EA202092159A1/en unknown
- 2019-09-27 WO PCT/CN2019/108483 patent/WO2020151252A1/en unknown
- 2019-09-27 AU AU2019424375A patent/AU2019424375B2/en active Active
- 2019-09-27 US US17/425,701 patent/US20220185774A1/en active Pending
- 2019-09-27 EP EP19911146.9A patent/EP3915972A4/en active Pending
- 2019-09-27 JP JP2021542370A patent/JP7479384B2/en active Active
- 2019-09-27 SG SG11202107774QA patent/SG11202107774QA/en unknown
- 2019-09-27 CN CN201980090023.7A patent/CN113365979B/en active Active
- 2019-09-27 CA CA3127393A patent/CA3127393A1/en active Pending
- 2019-09-27 KR KR1020217026389A patent/KR20210119452A/en active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
US20220185774A1 (en) | 2022-06-16 |
EP3915972A4 (en) | 2022-12-21 |
KR20210119452A (en) | 2021-10-05 |
AU2019424375A1 (en) | 2021-09-02 |
JP7479384B2 (en) | 2024-05-08 |
JP2022518258A (en) | 2022-03-14 |
CA3127393A1 (en) | 2020-07-30 |
WO2020151252A1 (en) | 2020-07-30 |
EA202092159A1 (en) | 2020-12-15 |
AU2019424375B2 (en) | 2023-07-13 |
CN113365979B (en) | 2023-09-22 |
CN113365979A (en) | 2021-09-07 |
EP3915972A1 (en) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202009150RA (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
SG11202107774QA (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof | |
EP3835296A4 (en) | Ketoamide compound and preparation method, pharmaceutical composition, and use thereof | |
EP3741374A4 (en) | Mtor inhibitor, pharmaceutical composition and use thereof | |
EP3412669A4 (en) | Tricyclic compound for bromodomain-containing protein inhibitor and preparation, pharmaceutical composition, and application thereof | |
EP3805264A4 (en) | Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof | |
EP3753943A4 (en) | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | |
EP3719017A4 (en) | Compound functioning as bromodomain protein inhibitor, and composition | |
EP3782998A4 (en) | Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof | |
EP3805234A4 (en) | Aromatic heterocyclic compound, and pharmaceutical composition and use thereof | |
EP3880671A4 (en) | Novel compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | |
EP3964512A4 (en) | CASEIN KINASE 1epsilon INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | |
EP4023227A4 (en) | Pharmaceutical composition and application thereof | |
GB201911517D0 (en) | Pharmaceutical composition | |
EP3868371A4 (en) | Novel pharmaceutical composition | |
EP3697411A4 (en) | Novel pharmaceutical composition and use thereof | |
EP3849992A4 (en) | Cd73 inhibitors and pharmaceutical uses thereof | |
EP3770148A4 (en) | Receptor inhibitor, pharmaceutical composition comprising same, and use thereof | |
EP3942968A4 (en) | Detachable five-star leg | |
EP3777866A4 (en) | Pharmaceutical composition and application thereof | |
GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof | |
DK3399040T3 (en) | PROCEDURE FOR THE PREPARATION OF PORCINE CIRCOVIRUS TYPE 2 CAPSID PROTEIN AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | |
IL276783A (en) | Novel compound and pharmaceutical composition compirisng same | |
EP3950677A4 (en) | Quinolyl-containing compound and pharmaceutical composition, and use thereof | |
EP3817744A4 (en) | Ivosidenib forms and pharmaceutical compositions |